World's Best Scientists 2026 revealed!
Frans M.J. Debruyne

Frans M.J. Debruyne

D-Index & Metrics

Medicine

D-Index
93
Citations
32664
World Ranking
10867
National Ranking
129

Frans M.J. Debruyne publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Frans M.J. Debruyne sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 802 publications — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Frans M.J. Debruyne D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Frans M.J. Debruyne sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 93 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Surgery
  • Cancer

Prostate, Surgery, Urology, Pathology and Prostate cancer are his primary areas of study. His research in Prostate focuses on subjects like Hyperplasia, which are connected to Adenoma. His work deals with themes such as Internal medicine, Carcinoma and Transurethral microwave thermotherapy, which intersect with Surgery.

His Urology research integrates issues from Lower urinary tract symptoms, Randomized controlled trial, Antiandrogen and Urinary system. His study in Pathology is interdisciplinary in nature, drawing from both Cancer, Cancer research, Cadherin and Cellular differentiation. His Prostate cancer research includes themes of High-mobility group, Magnetic resonance imaging and In situ hybridization.

His most cited work include:

  • DD3::A New Prostate-specific Gene, Highly Overexpressed in Prostate Cancer (884 citations)
  • Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. (568 citations)
  • Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. (565 citations)

What are the main themes of his work throughout his whole career to date?

Frans M.J. Debruyne mainly focuses on Surgery, Urology, Prostate, Internal medicine and Pathology. His work on Surgery is being expanded to include thematically relevant topics such as Bladder outlet obstruction. In the field of Urology, his study on Urinary bladder overlaps with subjects such as In patient.

Frans M.J. Debruyne combines subjects such as Radiology, Prostate cancer and Hyperplasia with his study of Prostate. The various areas that Frans M.J. Debruyne examines in his Internal medicine study include Gastroenterology, Endocrinology and Oncology. His Pathology research is multidisciplinary, incorporating elements of Cancer, Cancer research and Antibody.

He most often published in these fields:

  • Surgery (32.23%)
  • Urology (25.64%)
  • Prostate (20.77%)

What were the highlights of his more recent work (between 2001-2021)?

  • Surgery (32.23%)
  • Urology (25.64%)
  • Internal medicine (18.48%)

In recent papers he was focusing on the following fields of study:

His primary areas of study are Surgery, Urology, Internal medicine, Prostate cancer and Prostate. He works on Surgery which deals in particular with Randomized controlled trial. His work carried out in the field of Urology brings together such families of science as Lower urinary tract symptoms, Quality of life, Urinary system, Randomization and Prostate-specific antigen.

His research in Internal medicine intersects with topics in Endocrinology and Oncology. His Prostate cancer study integrates concerns from other disciplines, such as Clinical trial and Zoledronic acid. Frans M.J. Debruyne is interested in International Prostate Symptom Score, which is a branch of Prostate.

Between 2001 and 2021, his most popular works were:

  • Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. (207 citations)
  • Efficacy and Safety of Long-Term Treatment with the Dual 5α-Reductase Inhibitor Dutasteride in Men with Symptomatic Benign Prostatic Hyperplasia (199 citations)
  • Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial (154 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Surgery
  • Cancer

His primary areas of investigation include Surgery, Urology, Internal medicine, Quality of life and Tibial nerve. His Surgery study incorporates themes from Prostatectomy and General surgery. His Urology research incorporates elements of Lower urinary tract symptoms, Prostate, Urinary system, Randomization and Watchful waiting.

His Prostate research is multidisciplinary, relying on both Biopsy, Magnetic resonance imaging, Prostate cancer and Hazard ratio. His work on Nephrology, Erectile dysfunction, Randomized controlled trial and Gonadotropin-releasing hormone antagonist as part of general Internal medicine study is frequently linked to Vardenafil, therefore connecting diverse disciplines of science. He has included themes like Urination and Anesthesia in his Tibial nerve study.

Best Publications

  • DD3::A New Prostate-specific Gene, Highly Overexpressed in Prostate Cancer

    M.J.G. Bussemakers;A. van Bokhoven;G.W.C.T. Verhaegh;F.P. Smit

  • Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

    Donald L. Lamm;Ad P.M. Van Der Meijden;Alvaro Morales;Stanley A. Brosman

  • Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer.

    Umbas R;Schalken Ja;Aalders Tw;Carter Bs

  • Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.

    Marloes van der Leest;Erik Cornel;Bas Israël;Rianne Hendriks

  • Decreased E-Cadherin Expression Is Associated with Poor Prognosis in Patients with Prostate Cancer

    R. Umbas;W. B. Isaacs;P. P. Bringuier;H. E. Schaafsma

  • Decreased E-Cadherin Immunoreactivity Correlates with Poor Survival in Patients with Bladder Tumors

    P. P. Bringuier;R. Umbas;H. E. Schaafsma;H. F. M. Karthaus

  • Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial

    Abdel Rahmène Azzouzi;Sébastien Vincendeau;Eric Barret;Antony Cicco

  • 4–Year Follow–Up Results of a European Prospective Randomized Study on Neoadjuvant Hormonal Therapy prior to Radical Prostatectomy in T2–3N0M0 Prostate Cancer

    Claude C. Schulman;Frans M.J. Debruyne;Gerhard Forster;Francesco P. Selvaggi

  • Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study.

    Frans Debruyne;Gary Koch;Peter Boyle;Fernando Calais Da Silva

  • Efficacy and Safety of Long-Term Treatment with the Dual 5α-Reductase Inhibitor Dutasteride in Men with Symptomatic Benign Prostatic Hyperplasia

    Frans Debruyne;Jack Barkin;Peter van Erps;Mario Reis

  • Sustained-Release Alfuzosin, Finasteride and the Combination of Both in the Treatment of Benign Prostatic Hyperplasia

    F.M.J. Debruyne;A. Jardin;D. Colloi;L. Resel

  • Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors.

    Toru Shimazui;Jack A. Schalken;Laurence A. Giroldi;Cornelius F. J. Jansen

  • Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations

    E. David Crawford;Axel Heidenreich;Axel Heidenreich;Nathan Lawrentschuk;Bertrand Tombal

  • Predictability of Recurrent and Progressive Disease in Individual Patients with Primary Superficial Bladder Cancer

    L.A.L.M. Kiemeney;J.A. Witjes;R.P. Heijbroek;A.L.M. Verbeek

  • Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer.

    A P Verhagen;F C Ramaekers;T W Aalders;H E Schaafsma

  • POSTERIOR TIBIAL NERVE STIMULATION AS NEUROMODULATIVE TREATMENT OF LOWER URINARY TRACT DYSFUNCTION

    Michael R. van Balken;Vera Vandoninck;Karel W.H. Gisolf;Henk Vergunst

  • Decreased Expression of E-Cadherin in the Progression of Rat Prostatic Cancer

    Marion J. G. Bussemakers;Reindert J. A. van Moorselaar;Laurence A. Giroldi;Tomohiko Ichikawa

  • Molecular Genetics and Epidemiology of Prostate Carcinoma

    Emiel Ruijter;Christina van de Kaa;Gary Miller;Dirk Ruiter

  • Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis.

    H.G. van der Poel;J.A. Roukema;S. Horenblas;A.N. van Geel

  • Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration.

    Anja P. M. Verhagen;Tilly W. Aalders;Frans C. S. Ramaekers;Frans M. J. Debruyne

Frequent Co-Authors

Jack A. Schalken
Jack A. Schalken Radboud University
Lambertus A. Kiemeney
Lambertus A. Kiemeney Radboud University
Jean J.M.C.H. de la Rosette
Jean J.M.C.H. de la Rosette Istanbul Medipol University
Claude Schulman
Claude Schulman Université Libre de Bruxelles
Peter F.A. Mulders
Peter F.A. Mulders Radboud University
Richard Sylvester
Richard Sylvester European Organisation for Research and Treatment of Cancer
Alexandre R. Zlotta
Alexandre R. Zlotta University Health Network
Jelle O. Barentsz
Jelle O. Barentsz Radboud University
Arend Heerschap
Arend Heerschap Radboud University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering a career in medicine but seeking alternative or complementary paths, online nursing degrees are a flexible and affordable option. The growing need for skilled healthcare professionals means there are a variety of programs to fit different schedules and ambitions.

Those starting their journey may benefit from affordable nursing programs online, which provide foundational training for aspiring nurses. Registered nurses wanting to advance their skills and earning potential often pursue the rn to bsn cheapest programs to complete their bachelor’s degree at lower cost.

For those aiming for advanced practice roles, it's possible to enroll in affordable np programs that prepare students for the clinical and leadership demands of nurse practitioner careers. Alternatively, professionals interested in teaching, research, or leadership positions should consider a phd nursing education online to open doors in academia and healthcare administration.

Exploring these pathways allows students to contribute to healthcare in meaningful ways, often with the flexibility of online learning and the potential for reduced costs.

Best Scientists Citing Frans M.J. Debruyne

Trending Scientists

Recently Published Articles